China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will ...

GSK PLCGSK3.09%increase; green up pointing triangle extended its collaboration with Chongqing Zhifei Biological Products 300122-1.12%decrease; red down pointing triangle to commercialize its ...

The revised agreement extends the original 3-year period (2024-2026) during which Zhifei has exclusive rights to import, distribute and co-promote the vaccine in mainland China for an additional 8 ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix ...

(RTTNews) - GSK plc (GSK, GSK.L), on Thursday, said it has agreed with Chongqing Zhifei Biological Products Ltd. to revise the terms on which Zhifei will commercialize GSK's shingles vaccine ...